What will a hip option cost?

What belongs in the written price?

The quote should name the treatment, the hip area and each visit in the total. It should say whether scans, braces, medicines or later checks cost more.

If the clinic plans several visits, ask why your hip needs that schedule. Two quotes aren't equal when they cover different care or different sore areas.

Read the charge for each visit, not only the total at the bottom. That makes an added fee easier to spot before payment.

Will a health plan pay for PRP?

Coverage differs by health plan, and cash care may not be covered. Get the billing details from the clinic, then call your plan before paying.

The health plan's coverage decision only says whether it will pay. It doesn't say whether the treatment is likely to help your hip.

The exam still needs to name the sore area and likely cause. Then ask what was learned from people with the same hip problem.

What should happen before you pay?

Get the doctor's best current explanation for the soreness in writing. The same paper should list the full price, common risks and care after the procedure.

Ask whom to call if soreness rises after the visit. Don't let a short deadline take away time to read and ask questions.

Bring someone you trust when the terms or price are hard to track. The full amount matters more than a small discount offered that day.

Sources

1. CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only inside an approved coverage-with-evidence-development clinical research study. There is no national Medicare coverage of PRP for hip osteoarthritis or any other joint condition.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development).. CMS, 2026.

2. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

3. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

4. A 2025 review of mesenchymal stem cell injection research in orthopaedics identified 449 registered clinical trials, of which only 159 (35.4%) were complete and only 56 (12.5%) had published results in peer-reviewed journals. Hip and knee osteoarthritis were the most common indications (37.6%). Reported cell concentrations spanned three orders of magnitude and 55.5% of protocols did not specify a concentration at all.

   Bezuglov E, et al. — Mesenchymal stem cells injections in traumatology and orthopaedics: common practice or still a promising area with many uncertainties?. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-09123-8.